For Risk-Tolerant Investors, Pyxis Oncology Inc (NASDAQ: PYXS) Stands Out As A Strong Investment Choice

During the last session, Pyxis Oncology Inc (NASDAQ:PYXS)’s traded shares were 2.13 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $5.57, reflecting an intraday gain of 3.53% or $0.19. The 52-week high for the PYXS share is $6.85, that puts it down -22.98 from that peak though still a striking 75.76% gain since the share price plummeted to a 52-week low of $1.35. The company’s market capitalization is $323.78M, and the average intraday trading volume over the past 10 days was 1.17 million shares, and the average trade volume was 847.11K shares over the past three months.

Pyxis Oncology Inc (NASDAQ:PYXS) trade information

Pyxis Oncology Inc (PYXS) registered a 3.53% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.53% in intraday trading to $5.57, hitting a weekly high. The stock’s 5-day price performance is 45.43%, and it has moved by -13.91% in 30 days. Based on these gigs, the overall price performance for the year is 38.90%. The short interest in Pyxis Oncology Inc (NASDAQ:PYXS) is 1.63 million shares and it means that shorts have 1.84 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Pyxis Oncology Inc (PYXS) estimates and forecasts

Statistics show that Pyxis Oncology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Pyxis Oncology Inc (PYXS) shares have gone up 171.71% during the last six months, with a year-to-date growth rate more than the industry average at 54.05% against 8.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 56.40% this quarter and then jump 39.00% in the quarter after that.

Revenue for the current quarter is expected to be $4.12 million as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to $120k by the end of Jun 2024.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -118.72%. While earnings are projected to return 42.03% in 2024, the next five years will return 34.60% per annum.

PYXS Dividends

Pyxis Oncology Inc is due to release its next quarterly earnings between March 22 and March 26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders

Pyxis Oncology Inc insiders own 21.97% of total outstanding shares while institutional holders control 29.84%, with the float percentage being 38.24%. Laurion Capital Management, LP is the largest shareholder of the company, while 64 institutions own stock in it. As of Jun 29, 2023, the company held over 3.17 million shares (or 8.02% of all shares), a total value of $8.12 million in shares.

The next largest institutional holding, with 1.79 million shares, is of Tang Capital Management, LLC’s that is approximately 4.52% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $4.58 million.

Also, the Mutual Funds coming in first place with the largest holdings of Pyxis Oncology Inc (PYXS) shares are Vanguard Total Stock Market Index Fund and Tekla Healthcare Investors. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.75 million shares. This amounts to just over 1.89 percent of the company’s overall shares, with a $1.92 million market value. The same data shows that the other fund manager holds slightly less at 0.48 million, or about 1.22% of the stock, which is worth about $1.23 million.